Are new technologies translatable to point-of-care testing?
Lancet
.
2017 Dec 23;390(10114):2765-2766.
doi: 10.1016/S0140-6736(17)33301-9.
Authors
Danielle Bury
1
,
Pierre L Martin-Hirsch
2
,
Francis L Martin
1
,
Timothy P Dawson
3
Affiliations
1
School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Lancashire, Preston, UK.
2
Department of Gynaecology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, UK.
3
Department of Neuropathology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, UK. Electronic address:
[email protected]
.
PMID:
29303719
DOI:
10.1016/S0140-6736(17)33301-9
No abstract available
Publication types
Letter
MeSH terms
Humans
Inventions
Magnetic Resonance Spectroscopy
Neoplasms / diagnosis*
Point-of-Care Testing*
Spectrum Analysis
Translational Research, Biomedical
Vibration